This post was originally published on South China Morning Post.
Coronavirus: Chinese media champion Sinovac’s vaccine but not everybody is convinced
When Brazilian researchers announced lower-than-expected phase 3 results for a Chinese coronavirus vaccine clinical trial, the response was swift.Various regulators around the world said they would take a close look at the data for Sinovac Biotech’s CoronaVac product, which the company’s Brazilian partner, the Butantan Institute, said on Tuesday had a roughly 50 per cent general efficacy rate – well below the 78 per cent reported earlier.But there was little mention in Chinese media on Thursday…